自免疫性肝炎:面向个性化治疗
Alejandro Costaguta1, Guillermo Costaguta2, Fernando Álvarez3
1Department of Hepatology and Liver Transplant Unit, Sanatorio de Niños de Rosario, Rosario 2000, Santa Fe, Argentina. alejandro.costaguta@gmail.com.
World journal of hepatology
|November 28, 2024
概括
自免疫性肝炎的治疗方法在很大程度上保持不变,尽管有进展. 本综述探讨了当前和新兴疗法,包括类固醇,免疫抑制剂和新生物药物,以改善患者的治疗结果.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 自身免疫性肝炎 (AIH) 是一种慢性肝炎,影响成人和儿童,其特征是高IgG和自身抗体水平.
- 目前的标准治疗包括类固醇和阿扎西奥普林,在约80%的患者中实现了缓解.
- 尽管免疫学方面取得了重大进展,但AIH的治疗算法在40多年来几乎没有任何更新.
研究的目的:
- 审查目前对自身免疫性肝炎的治疗选择.
- 讨论既有和新兴疗法的疗效和局限性.
- 探索个性化AIH治疗的未来方向.
主要方法:
- 对自身免疫性肝炎的可用治疗方案的文献综述.
- 对各种免疫抑制剂和生物药物的临床经验进行分析.
- 讨论正在研究的新型治疗策略.
主要成果:
- 类固醇是诱导的标准,但像环素A和塔克罗利斯这样的替代品显示出希望,尽管有潜在的副作用.
- 菌酸莫菲蒂尔是阿扎西奥普林不耐受患者的选择.
- B细胞消耗剂 (利图西马布,贝利穆马布) 对耐火AIH有效.
- 新兴疗法包括抗TNF药物,JAK抑制剂和CAR T细胞疗法.
结论:
- 虽然类固醇和阿扎西奥普林仍然是基础,但现在对AIH有更广泛的治疗方案.
- 新的药物为诱导,维持和耐火性疾病提供了替代方案.
- 未来的AIH管理可能涉及基于个体患者资料的量身定制的治疗方法.
相关概念视频
Autoimmune Disorders
389
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
Concept and Mechanism of Autoimmune Diseases
The immune...
389
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Myasthenia Gravis: Overview and Treatment
1.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.2K
Tumor Immunotherapy
480
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
480
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
117
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117
Inflammatory Bowel Disease IV: Pharmacological Management
113
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
113


